The B chain, but not the A chain, of Ricinus communis activates human complement

Cancer Lett. 1993 Nov 30;75(1):59-63. doi: 10.1016/0304-3835(93)90208-q.

Abstract

Complement activation properties of ricin holotoxin, its A or B chain were assessed in two enzyme immunoassays (EIA). One was specific for C3 activation products and the other detected the terminal SC5b-9 complement complex (TCC) and thus determined activation of the initial and terminal part of the complement pathways, respectively. Ricin and its A and B chains were incubated with normal human serum or EDTA-serum. It was found that ricin B chain activated both the initial and terminal complement pathways in a time- and concentration-dependent fashion, whereas the A chain and the holotoxin did not.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Complement Activation*
  • Complement C3 / metabolism*
  • Complement C5 / metabolism*
  • Complement C5b
  • Dose-Response Relationship, Drug
  • Edetic Acid / pharmacology
  • Humans
  • Immunoenzyme Techniques
  • In Vitro Techniques
  • Ricin / pharmacology*

Substances

  • Complement C3
  • Complement C5
  • Complement C5b
  • Ricin
  • Edetic Acid